Physician profile
Prabhdeep Singh
NPI 1225021587
$9,014.40
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $2,110 · 2021: $2,535 · 2022: $1,422 · 2023: $819 · 2024: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,220.63 | 2019-2024 | Airsupra, Lokelma, Farxiga |
| Corcept Therapeutics | $1,177.32 | 2020-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $802.31 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $683.28 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Kowa Pharmaceuticals America, INC. | $617.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $525.10 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $463.25 | 2019-2024 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $328.82 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $325.94 | 2019-2023 | |
| Amgen INC. | $277.02 | 2019-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.17 | 2020-2024 | Jardiance |
| Abbvie INC. | $204.97 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $194.36 | 2019-2021 | |
| Allergan, INC. | $184.98 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.67 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhdeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.